Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating today.
Joseph Stringer has given his Hold rating due to a combination of factors impacting Moderna’s financial outlook. The company’s reported revenue for the fourth quarter of 2024 was $1.0 billion, which matched their earlier preannouncement. Although the earnings per share exceeded Needham’s expectations, it fell short of the consensus estimate. Moderna has maintained its guidance for 2025 revenue, projecting a range between $1.5 to $2.5 billion, and expects to have $6.0 billion in cash by the end of 2025.
Despite these projections, the company faces ongoing challenges with its product revenue, emphasizing the importance of cost-cutting and efficiency measures. Additionally, while the Oncology/INT franchise presents significant long-term value potential, its immediate impact on driving revenue growth is uncertain. These factors collectively contribute to the Hold rating, reflecting a cautious optimism about the company’s future performance.
According to TipRanks, Stringer is a 2-star analyst with an average return of 0.2% and a 38.17% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Vertex Pharmaceuticals, and Alnylam Pharma.
In another report released today, TD Cowen also maintained a Hold rating on the stock with a $35.00 price target.